Introduction: AIHA is a complex and heterogeneous disease involving antigen-autoantibody reaction, T-cell co-stimulation, complement activation, phagocytosis and bone marrow compensatory response. Several drugs targeting these mechanisms are under development in addition to standard therapies: steroids, immunesuppressors and splenectomy. Areas covered: Rituximab is the first biologic therapy used in AIHA, and its association with bendamustine and fludarabine has been shown more effective in relapse/refractory cold agglutinin disease. In these cases bortezomib was also beneficial with an overall response in about 30% of cases, and several complement inhibitors (eculizumab, BIVV009, and APL-2) are currently under investigation. B-cell receptor inhibitors (ibrutinib, acalabrutinib, and idelalisib) are promising therapeutic options for lymphoproliferative associated secondary forms. Finally, targeting IgG driven extravascular hemolysis (SYNT001 and fostamatinib) is an exciting new treatment approach. Expert opinion: AIHAs have been historically considered benign and easy to treat, however relapsing/refractory cases represent a clinical challenge. In these cases a target therapy would be ideal as traditional treatments are often ineffective/unfeasible. Moreover, the several mechanisms involved may be variably acting in the single patient and unpredictably changing overtime. Since several exciting target-therapies are emerging, only prospective studies would clarify the best choice, association, and sequence of these new drugs.
Autoimmune hemolytic anemia - progress in emerging treatment options / W. Barcellini, B. Fattizzo. - In: EXPERT OPINION ON ORPHAN DRUGS. - ISSN 2167-8707. - 6:4(2018), pp. 273-282.
|Titolo:||Autoimmune hemolytic anemia - progress in emerging treatment options|
FATTIZZO, BRUNO (Corresponding)
|Parole Chiave:||autoimmune haemolytic anemia; cold agglutinin disease; complement; rituximab|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/21678707.2018.1452734|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Autoimmune hemolytic anemia progress in emerging treatment options.pdf||Publisher's version/PDF||Administrator Richiedi una copia|